Advanced search
Publication Cover
Emerging Microbes & Infections Volume 12, 2023 - Issue 1
Submit an article Journal homepage
2,338
Views
1
CrossRef citations to date
0
Altmetric
Tuberculosis

Efficacy and safety of an innovative short-course regimen containing clofazimine for treatment of drug-susceptible tuberculosis: a clinical trial

Xubin Zhenga Clinic and Research Centre of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People’s Republic of ChinaView further author information
,
Xuwei Guia Clinic and Research Centre of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People’s Republic of ChinaView further author information
,
Lan Yaoa Clinic and Research Centre of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People’s Republic of ChinaView further author information
,
Jun Maa Clinic and Research Centre of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People’s Republic of ChinaView further author information
,
Yifan Hea Clinic and Research Centre of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People’s Republic of ChinaView further author information
,
Hai Loua Clinic and Research Centre of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People’s Republic of ChinaView further author information
,
Jin Gua Clinic and Research Centre of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People’s Republic of ChinaView further author information
,
Ruoyan Yinga Clinic and Research Centre of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People’s Republic of ChinaView further author information
,
Liping Chena Clinic and Research Centre of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People’s Republic of ChinaView further author information
,
Qin Suna Clinic and Research Centre of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People’s Republic of ChinaView further author information
,
Yidian Liua Clinic and Research Centre of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People’s Republic of ChinaView further author information
,
Chih-Ming Hob Department of Mechanical and Aerospace Engineering, University of California, Los Angeles, CA, USA;c Department of Bioengineering, University of California, Los Angeles, CA, USAView further author information
,
Bai-Yu Leed Division of Infectious Diseases, Department of Medicine, University of California, Los Angeles, CA, USAView further author information
,
Daniel L. Clemensd Division of Infectious Diseases, Department of Medicine, University of California, Los Angeles, CA, USAView further author information
,
Marcus A. Horwitzd Division of Infectious Diseases, Department of Medicine, University of California, Los Angeles, CA, USAView further author information
,
Xianting Dinge Institute for Personalized Medicine, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, People’s Republic of ChinaView further author information
,
Xiaohui Haoa Clinic and Research Centre of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
View further author information
,
Hua Yanga Clinic and Research Centre of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
View further author information
&
Wei Shaa Clinic and Research Centre of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Article: 2187247 | Received 29 Sep 2022, Accepted 01 Mar 2023, Published online: 17 Mar 2023

References

  • WHO. Global tuberculosis report 2021 Geneva: World Health Organization. [cited 2021]. Available from: https://www.who.int/publications/i/item/9789240037021; 2021
  • Tornheim JA, Dooley KE. The global landscape of tuberculosis therapeutics. Annu Rev Med. 2019 Jan 27;70:105–120. doi:10.1146/annurev-med-040717-051150. PubMed PMID: 30403551.
  • Grace AG, Mittal A, Jain S, et al. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis. Cochrane Db Syst Rev. 2019;12, doi:10.1002/14551858.CD012918.pub2. PubMed PMID: 31828771 WOS:000505243400024; English.
  • Dorman SE, Nahid P, Kurbatova EV, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. New Engl J Med. 2021 May 6;384(18):1705–1718. doi:10.1056/NEJMoa2033400. PubMed PMID: 33951360 WOS:000647698500009; English.
  • WHO. WHO consolidated guidelines on tuberculosis Module 4: treatment - drug-susceptible tuberculosis treatment Geneva2022 [updated 2022 May]. Available from: https://www.who.int/publications/i/item/9789240048126
  • Guglielmetti L, Gunther G, Leu C, et al. Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. Eur Respir J. 2022 May;59(5). doi:10.1183/13993003.00388-2022. PubMed PMID: 35589114.
  • Tyagi S, Ammerman NC, Li SY, et al. Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis. Proc Natl Acad Sci U S A. 2015 Jan 20;112(3):869–874. doi:10.1073/pnas.1416951112. PubMed PMID: 25561537; PubMed Central PMCID: PMCPMC4311815.
  • Swanson RV, Adamson J, Moodley C, et al. Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis. Antimicrob Agents Chemother. 2015;59(6):3042–3051. doi:10.1128/AAC.00260-15. PubMed PMID: 25753644; PubMed Central PMCID: PMCPMC4432183.
  • Saini V, Ammerman NC, Chang YS, et al. Treatment-Shortening effect of a novel regimen combining clofazimine and high-dose rifapentine in pathologically distinct mouse models of tuberculosis. Antimicrob Agents Chemother. 2019 Jun;63(6). doi:10.1128/AAC.00388-19. PubMed PMID: 30936097; PubMed Central PMCID: PMCPMC6535519.
  • Ammerman NC, Swanson RV, Tapley A, et al. Clofazimine has delayed antimicrobial activity against mycobacterium tuberculosis both in vitro and in vivo. J Antimicrob Chemother. 2017 Feb;72(2):455–461. doi:10.1093/jac/dkw417. PubMed PMID: 27798204.
  • Lee BY, Clemens DL, Silva A, et al. Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time. Nat Commun. 2017 Jan 24;8:14183. doi:10.1038/ncomms14183. PubMed PMID: 28117835; PubMed Central PMCID: PMCPMC5287291.
  • Silva A, Lee BY, Clemens DL, et al. Output-driven feedback system control platform optimizes combinatorial therapy of tuberculosis using a macrophage cell culture model. Proc Natl Acad Sci U S A. 2016 Apr 12;113(15):E2172-9. doi:10.1073/pnas.1600812113. PubMed PMID: 27035987; PubMed Central PMCID: PMCPMC4839402.
  • WHO. Guidelines for treatment of drug-susceptible tuberculosis and patient care, Geneva 2017 [updated 2017 April]. Available from: https://www.who.int/publications/i/item/9789241550000
  • WHO. Definitions and reporting framework for tuberculosis – 2013 revision [updated 2014 Dec and 2020 Jan], Geneva 2020 [updated 2020 Jan]. Available from: https://www.who.int/publications/i/item/9789241505345
  • Linh NN, Viney K, Gegia M, et al. World Health Organization treatment outcome definitions for tuberculosis: 2021 update. Eur Respir J. 2021 Aug;58(2). doi:10.1183/13993003.00804-2021. PubMed PMID: 34413124.
  • U.S. Department of Health and Human Services NIoH, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1 2017. Available from: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf
  • Reuben A. Hy's law. Hepatology. 2004 Feb;39(2):574–578. doi:10.1002/hep.20081. PubMed PMID: 14768020.
  • Ding X, Sanchez DJ, Shahangian A, et al. Cascade search for HSV-1 combinatorial drugs with high antiviral efficacy and low toxicity. Int J Nanomedicine. 2012;7:2281–2292. doi:10.2147/IJN.S27540. PubMed PMID: 22654513; PubMed Central PMCID: PMCPMC3363951.
  • Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014 Jun;74(8):839–854. doi:10.1007/s40265-014-0222-8. PubMed PMID: 24846578.
  • Lan Z, Ahmad N, Baghaei P, et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2020 Apr;8(4):383–394. doi:10.1016/S2213-2600(20)30047-3. PubMed PMID: 32192585; PubMed Central PMCID: PMCPMC7384398.
  • Kahan BC, Cro S, Dore CJ, et al. Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials. Trials. 2014 Nov 21;15:456. doi:10.1186/1745-6215-15-456. PubMed PMID: 25416527; PubMed Central PMCID: PMCPMC4247637.
  • Kahan BC, Dore CJ, Murphy MF, et al. Bias was reduced in an open-label trial through the removal of subjective elements from the outcome definition. J Clin Epidemiol. 2016 Sep;77:38–43. doi:10.1016/j.jclinepi.2016.05.008. PubMed PMID: 27262238.
  • Chedore P, Bertucci L, Wolfe J, et al. Potential for erroneous results indicating resistance when using the bactec MGIT 960 system for testing susceptibility of mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol. 2010 Jan;48(1):300–301. doi:10.1128/Jcm.01775-09. PubMed PMID: 19923479 WOS:000276151500044; English.
  • Zhang Y, Permar S, Sun ZH. Conditions that may affect the results of susceptibility testing of mycobacterium tuberculosis to pyrazinamide. J Med Microbiol. 2002 Jan;51(1):42–49. doi:10.1099/0022-1317-51-1-42. PubMed PMID: 11800471 WOS:000173090900009; English.
  • WHO. Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis. Geneva: World Health Organization; 2018 [cited 2021]. Available from: https://www.who.int/tb/publications/2018/WHO_technical_drug_susceptibility_testing/en/
  • Lee BY, Clemens DL, Silva A, et al. Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility. PLoS One. 2018;13(11):e0207469. doi:10.1371/journal.pone.0207469. PubMed PMID: 30427938; PubMed Central PMCID: PMCPMC6235396.
  • Clemens DL, Lee BY, Silva A, et al. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs. PLoS One. 2019;14(5):e0215607. doi:10.1371/journal.pone.0215607. PubMed PMID: 31075149; PubMed Central PMCID: PMCPMC6510528.
  • Horwitz MA, Clemens DL, Lee B-Y. AI-Enabled Parabolic response surface approach identifies ultra short-course near-universal TB drug regimens. Adv. Ther. 2020;3(4):1900086. doi:10.1002/adtp.201900086.
  • [Technical guidelines for tuberculosis control and treatment in China]. Beijing: Chinese Center for Disease Control and Prevention; 2021.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.